The objective of this study was to estimate the cost effectiveness of imatinib mesylate in the treatment of GIST. Methods: A cost-effectiveness model of GIST treatment was developed. Long- term ...

The cost effectiveness of imatinib mesylate was estimated by extrapolating long-term survival and costs from the pivotal multicentre trial of 147 patients with advanced GIST receiving imatinib ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the ...

For most of the 20th century, doctors treated cancer by hitting it with everything they had. Radical surgery, high-dose radiation, brutal chemotherapy. Even when it worked, the collateral damage ...

Imatinib (IMKELDI) is the first oral liquid TKI approved for GIST, MDS, MPD, CML, and Ph+ ALL, enhancing treatment accessibility. The oral solution offers precise dosing, benefiting patients with ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of ...

The FDA has approved imatinib oral solution (Imkeldi) for the treatment of certain forms of leukemia and other cancers. This is the first oral liquid form of imatinib for the treatment of select ...